Donna M. Graham

1.9k total citations
64 papers, 1.1k citations indexed

About

Donna M. Graham is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Donna M. Graham has authored 64 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 14 papers in Cancer Research. Recurrent topics in Donna M. Graham's work include Cancer Genomics and Diagnostics (13 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Lung Cancer Treatments and Mutations (10 papers). Donna M. Graham is often cited by papers focused on Cancer Genomics and Diagnostics (13 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Lung Cancer Treatments and Mutations (10 papers). Donna M. Graham collaborates with scholars based in United Kingdom, Canada and United States. Donna M. Graham's co-authors include Natasha B. Leighl, Grzegorz Korpanty, Mark Vincent, Ora E. Johannsson, Éric Millard, Lillian L. Siu, Michael S. Blaiss, Natalie Cook, Louise Carter and Fiona Thistlethwaite and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Donna M. Graham

59 papers receiving 1.0k citations

Peers

Countries citing papers authored by Donna M. Graham

Since Specialization

Citations

This map shows the geographic impact of Donna M. Graham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donna M. Graham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donna M. Graham more than expected).

Fields of papers citing papers by Donna M. Graham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donna M. Graham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donna M. Graham. The network helps show where Donna M. Graham may publish in the future.

Co-authorship network of co-authors of Donna M. Graham

This figure shows the co-authorship network connecting the top 25 collaborators of Donna M. Graham. A scholar is included among the top collaborators of Donna M. Graham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donna M. Graham. Donna M. Graham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-world experience of Molecular Tumour Boards for clinical decision-making for cancer patients 2025 ·npj Precision Oncology ·(unknown), (unknown), Kate Duffus, Zoulikha M. Zaïr, Fiona Thistlethwaite, Matthew Krebs, Louise Carter, Donna M. Graham, Natalie Cook	0
2	Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study 2024 ·Cancer ·Hyun Cheol Chung, Esma Saâda-Bouzid, Federico Longo, Eduardo Yáñez, Seock‐Ah Im, Eduardo Castañón, Danielle Desautels, Donna M. Graham, Javier García-Corbacho, Juanita Lopez, Corina E. Dutcus, Chinyere E. Okpara, Razi Ghori, Fan Jin, Roman Groisberg, (unknown)	4
3	Social determinants of health inequalities in early phase clinical trials in Northern England 2024 ·British Journal of Cancer ·S. C. Rae, (unknown), E. Taylor, (unknown), (unknown), H. Löwe, (unknown), Saira Bashir, Christoph Oing, Matthew Krebs, Fiona Thistlethwaite, (unknown), Natalie Cook, Alastair Greystoke, Donna M. Graham, (unknown)	2
4	Examining clinical trial eligibility for oncology patients with human immunodeficiency virus (HIV): A global cross-sectional analysis. 2023 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), (unknown), David R. Appleton, Matthew J. Concannon, Donna M. Graham	1
5	158P Enhancing the communication of genomic results: Understanding patient and clinician perspectives 2023 ·ESMO Open ·(unknown), (unknown), Lynne Goodwin, Zoulikha M. Zaïr, (unknown), Matthew Krebs, Donna M. Graham, Fiona Thistlethwaite, (unknown), Natalie Cook	1
6	Digital ECMT Cancer Trial Matching Tool: an Open Source Research Application to Support Oncologists in the Identification of Precision Medicine Clinical Trials 2023 ·JCO Clinical Cancer Informatics ·(unknown), (unknown), (unknown), Julie-Anne Stevenson, Hannah Frost, Donna M. Graham, Matthew Krebs, André Freitas, Dónal Landers	5
7	Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study 2022 ·European Journal of Cancer ·Patricio Serra-Bellver, Judith M. Versluis, (unknown), Cong Zhou, (unknown), Yasir Khan, James R. Patrinely, Inês Pires da Silva, Clara Martínez-Vila, Natalie Cook, Donna M. Graham, Matteo S. Carlino, Alexander M. Menzies, Ana Arance, Douglas B. Johnson, Georgina V. Long, Lisa Pickering, James Larkin, Christian U. Blank, Paul Lorigan	14
8	Patient attrition in Molecular Tumour Boards: a systematic review 2022 ·British Journal of Cancer ·Hannah Frost, Donna M. Graham, Louise Carter, (unknown), Dónal Landers, André Freitas	5
9	529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors 2021 ·SHILAP Revista de lepidopterología ·Eric Van Cutsem, Hans Prenen, (unknown), Kristen Spencer, Tara C. Mitchell, Howard A. Burris, Nuria Kotecki, Rebecca Kristeleit, David J. Pinato, Solmaz Sahebjam, Donna M. Graham, Thomas B. Karasic, (unknown), Kevin O’Hayer, Ryan Geschwindt, Sarina A. Piha‐Paul	11
10	A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer 2021 ·Lung Cancer ·Andrea S. Fung, Donna M. Graham, Eric X. Chen, Tracy Stockley, Tong Zhang, Lisa W. Le, Hamzeh Albaba, Katherine M.W. Pisters, Penelope A. Bradbury, Martina Trinkaus, Matthew Chan, (unknown), Urszula Zurawska, J. Rothenstein, (unknown), (unknown), (unknown), (unknown), (unknown), Natasha B. Leighl	9
11	LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours 2020 ·Annals of Oncology ·Zarnie Lwin, Carlos Gomez‐Roca, Esma Saâda-Bouzid, (unknown), (unknown), S-A. Im, Eduardo Castañón, Hélène Senellart, Donna M. Graham, Martin H. Voss, Mark Doherty, Juanita Lopez, Razi Ghori, Peter Kubiak, Fan Jin, Kevin Norwood, Hyun Cheol Chung	59
12	P2.13-33 A Case Report of Exceptional Clinical Response to MEK Inhibition in a Patient with NRAS Mutation Positive NSCLC 2018 ·Journal of Thoracic Oncology ·Matthew Krebs, Donna M. Graham, Mahmood Ayub, (unknown), Hannah Frost, (unknown), Bedirhan Kilerci, Andrew J. Wallace, (unknown), (unknown), (unknown), (unknown), Nandini Maharaj, (unknown), Mandar Bhonde, Kristopher K. Frese, Caroline Dive, Dominic G. Rothwell, Gerard Brady	1
13	Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer 2016 ·Current Colorectal Cancer Reports ·Donna M. Graham, Vicky M. Coyle, Richard D. Kennedy, Richard H. Wilson	28
14	Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS 2014 ·Frontiers in Oncology ·Grzegorz Korpanty, Donna M. Graham, Mark Vincent, Natasha B. Leighl	132
15	Could the human papillomavirus vaccination be cost-effective in males for the prevention of oropharyngeal cancer? 2014 ·Expert Review of Pharmacoeconomics & Outcomes Research ·Wanrudee Isaranuwatchai, Donna M. Graham, Lillian L. Siu, Jeffrey S. Hoch	9
16	The Cost-Effectiveness of Second-Line Crizotinib in Eml4-Alk Rearranged Advanced Non-Small Cell Lung Cancer 2014 ·Value in Health ·(unknown), Donna M. Graham, Jaclyn Beca, Jeffrey S. Hoch, Ming‐Sound Tsao, Natasha B. Leighl	1
17	The Use of Complementary and Alternative Medicine by Irish Pediatric Cancer Patients 2013 ·Journal of Pediatric Hematology/Oncology ·(unknown), Donna M. Graham, Anne T. OʼMeara, (unknown), (unknown), Denise O’Leary, Maeve O’Reilly	17
18	Ocular wounding prevents pre-retinal neovascularization and upregulates PEDF expression in the inner retina. 2004 ·PubMed ·Alan W. Stitt, Donna M. Graham, Tom A. Gardiner	17
19	Assessment of Abundance, Biomass and Production of the Lower Trophic Levels in the Eastern Basin of Lake Erie, 1994 1996 ·SUNY Digital Repository Support (State University of New York System) ·Donna M. Graham, (unknown), Éric Millard, Ora E. Johannsson, (unknown)	7
20	Lake Erie 1993, Western, West Central and Eastern Basins: Change in Trophic Status, and Assessment of the Abundance, Biomass and Production of the Lower Trophic Levels 1995 ·SUNY Digital Repository Support (State University of New York System) ·(unknown), Donna M. Graham, Ora E. Johannsson, Éric Millard, (unknown)	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact